What Estrumate Treats: Main Uses and Benefits

Estrumate is commonly used to help manage symptoms and conditions related to the female reproductive system. Its therapeutic applications fall into several key areas, relevant in contexts involving heightened systemic burden.

---

This medication is applied across domains where additional symptomatic support is needed, including the management of irregular or unobserved heat cycles, the resolution of physical reproductive tract issues like chronic endometritis and mummified fetuses, and the therapeutic management of unwanted pregnancy. This application assists with maintaining functional stability and supports general well-being during symptomatic phases.

“Estrumate helps address symptom clusters related to physical reproductive tract issues, providing supportive relief.”

---

Timing and Regulating Reproductive Cycles

This medication is used for managing symptoms of irregular, delayed, or unobserved heat cycles. It plays a role in managing the timing of the cycle for breeding programs and assists with maintaining functional stability by supporting estrus synchronization.

Resolving Uterine and Post-Partum Issues

It helps address symptom clusters related to physical reproductive tract issues, such as chronic endometritis (pyometra) and mummified fetuses. This use provides supportive relief and may assist with managing the return to cyclical function after the resolution of retention issues.

Therapeutic Management of Unwanted Pregnancy

Estrumate is applied in situations where there is a need to terminate a pregnancy for health or management reasons. This contributes to easing the overall symptom load associated with an unwanted pregnancy status.

---

Quick Fact: Relevant for Irregular Reproductive Cycles

Regulatory References

1. FDA DailyMed Label for Estrumate

Who Can and Cannot Use Estrumate (Cloprostenol)?

Estrumate is a prescription-only veterinary medicine with specific regulatory eligibility rules defined by official government documents. Eligibility is determined by animal species, reproductive status, and the presence of certain underlying conditions.

---

Populations and Conditions for Use

Classification	Criteria from Official Labeling
Eligible Populations	Cattle (Beef and Dairy) and Horses (Mares) that are reproductively mature and cycling
Conditional Use	Pregnant animals only when the goal is therapeutic abortion or induction of parturition at a specified stage
Absolute Contraindication	Animals with known hypersensitivity to Cloprostenol
Absolute Contraindication	Pregnant animals where the maintenance of the pregnancy is desired
Restricted Use	Animals with acute vascular diseases or spastic respiratory conditions (e.g., severe asthma or pre-existing bronchial disease)

---

The medicine is restricted to use in target livestock species. Its primary regulatory constraint is its powerful effect on the reproductive cycle, making it strictly contraindicated if pregnancy is to be maintained. Use is further prohibited in animals with certain pre-existing conditions that may be exacerbated, such as compromised cardiovascular or respiratory function.

Interactions with other medicines and products

The interaction profile of Estrumate (Cloprostenol sodium) is defined by its core action as a prostaglandin analog, focusing exclusively on official documented pharmacodynamic effects with co-administered substances. Regulatory documents do not specify clinically relevant pharmacokinetic interactions, timing-based separation requirements, or interactions with food or herbal products.

---

Official Interaction Statements

The following co-administration restrictions and outcomes are documented in authoritative government regulatory sources, such as the Summary of Product Characteristics (SPC):

Interacting Substance/Class	Official Interaction Pattern
Non-steroidal anti-inflammatory drugs (NSAIDs)	Prohibited Co-administration: Official labeling advises against concomitant use due to pharmacodynamic antagonism. This is based on NSAIDs inhibiting endogenous prostaglandin synthesis, which opposes the intended luteolytic effect.
Oxytocin	Reinforcement: Co-administration leads to an increase in effects on the uterus, documenting an additive uterotonic response.
Progestogens	Antagonism: Co-administration results in a decreased effect of cloprostenol, diminishing its intended luteolytic action.

---

Interaction-Related Restrictions

Official regulatory sources explicitly state that Estrumate must not be administered concomitantly with Non-steroidal anti-inflammatory drugs (NSAIDs).

️ Targeted FP Receptor Agonism and Metabolic Stability

Cloprostenol is a selective agonist that activates the FP Prostanoid Receptor, the primary biological target located on luteal cells and uterine smooth muscle. A key mechanistic feature is its structural resistance to the catabolic enzyme 15-hydroxyprostaglandin dehydrogenase (≈15-PGDH), which allows the luteolytic signal to be sustained for a prolonged period, resulting in the full functional regression of the Corpus Luteum.

Luteolytic Cascade and Hormonal Axis Modulation

Sustained receptor activation initiates the luteolytic cascade, causing the Corpus Luteum to cease progesterone synthesis, which leads to a dramatic systemic drop in progesterone concentration. This removal of negative feedback on the Hypothalamic-Pituitary-Gonadal (HPG) axis permits the subsequent pulsatile release of ≈FSH and ≈LH to begin new follicular development.

️ Stage-Dependent Mechanism and Uterine Modulation

The luteolytic mechanism is intrinsically constrained by the physiological state of the target tissue: it is not functional during the first few days post-ovulation because the luteal cells lack sufficient ≈FP receptor expression. Separately, the mechanism also stimulates myometrial smooth muscle contraction and uterine muscle tone.

Administration Guidelines: How to Use Estrumate

Estrumate (cloprostenol injection) is an injectable medicine administered in a specific manner following established protocols. It is crucial that the administration adheres precisely to the instructions detailed in the product labeling.

Official Administration Protocol

Administration Scope	Specification (Cattle)
Route	Intramuscular Injection
Standard Dose	2 mL (equivalent to 500 μg cloprostenol)
Timing Relative to Meals	Not specified (Parenteral product)
Preparation	Use aseptic technique; do not puncture the stopper more than 12 times for 100 mL vials.

Dosing and Timing for Use

The frequency and timing of Estrumate administration depend entirely on the specific management regimen being followed:

• Single Injection: For animals not detected in heat, a single 2 mL intramuscular injection is given. If estrus is not detected, insemination may occur twice at about 72 and 96 hours post-injection.
• Double Injection: This regimen involves two 2 mL intramuscular injections administered 11 days apart to a group of animals to synchronize their cycles.
• Fixed-Time Protocol: When used as part of a fixed-time artificial insemination protocol (e.g., with a GnRH product), a 2 mL Estrumate injection is administered 6 to 8 days after the first GnRH injection, followed by the second GnRH injection 30 to 72 hours later, and then artificial insemination 8 to 24 hours after the final GnRH injection.

Procedural Requirement: The use of a clean, single-use, hypodermic needle is required for administration to maintain careful aseptic techniques and minimize the risk of post-injection infection.

Research Evidence / Overview of Studies for Estrumate

Estrumate (Cloprostenol) has been the subject of regulatory and scientific research primarily conducted in controlled field settings and randomized comparative trials. This overview describes the type of evidence that exists, what outcomes were monitored in the studies, and what areas remain uncertain, according to official regulatory summaries and peer-reviewed scientific literature.

---

Evidence for Use in Estrus Synchronization

Research exploring the synchronization of heat cycles has largely involved short-term comparative studies and Randomized Controlled Trials (RCTs). These studies monitored outcomes related to physical discomfort and systemic or functional imbalance by looking at the specific time between the administration of the drug and the observable onset of estrus (heat). They also tracked subsequent reproductive outcomes, such as conception rates, and overall pregnancy rates following insemination.

Studies monitored short-term changes in the timing of the reproductive cycle, with findings describing patterns related to estrus onset in the observed populations. Regulatory submissions described the measurement of pregnancy rates in groups receiving synchronization protocols compared to other management systems. However, data show patterns related to significant variation in conception rates and overall pregnancy success. Findings were often mixed, suggesting that measured change was associated with the specific protocol used and other environmental or management factors not directly controlled by the study.

---

Evidence for Management of Uterine and Ovarian Issues

Estrumate was studied for its role in conditions involving periods of heightened symptoms related to the reproductive tract, such as pyometra (uterine infection) and chronic endometritis. Researchers also examined the physical resolution of the uterine contents and the return of the animal to normal cyclical activity.

Research describes observations of uterine evacuation and subsequent physical regression of the corpus luteum structure. Clinical data show patterns related to these changes in the observed populations, and studies report how symptoms evolved related to a measurable return to estrus and normal cycling. Similarly, research examined the physical regression of luteal cysts, and studies monitored the physical change, recording the co-occurrence of a measurable return to estrus.

---

What Remains Unclear or Under Study

The current evidence landscape highlights several limitations and areas of uncertainty. Sample sizes were modest in some specific clinical contexts, and results apply only to the populations studied. Comparative evidence is lacking or limited against untreated control groups in certain observational studies.

Furthermore, evidence quality varies across studies, particularly field studies, leading to mixed findings regarding the reliability of subsequent conception rates in synchronization protocols. The evidence helps contextualize how the medicine was evaluated but emphasizes that long-term effects are not fully established and that outcomes may be influenced by management factors outside the research control.

Key Studies & References Label: ESTRUMATE- cloprostenol sodium injection - DailyMed (Official FDA Label and Evidence Summary)

Common questions about Estrumate (FAQ)

---

Q: How quickly does Estrumate typically start working?

Estrumate is described as having the primary function of causing luteolysis, which is the functional regression of the Corpus Luteum. Official product information indicates that the result of this action, the onset of estrus (or heat), typically appears in normal cycling animals between 2 and 5 days following the administration of the injection.

---

Q: What is the difference between Estrumate and similar prostaglandins?

Estrumate's active ingredient, cloprostenol, is a synthetic prostaglandin analogue. Studies examining its pharmacological profile describe that cloprostenol does not exhibit thromboxane A2 activity, unlike some other prostaglandin analogues. This characteristic means the drug is noted in official information as not causing platelet aggregation.

---

Q: How long does the effect of Estrumate last in the body?

The drug is described in regulatory documents as sustaining a luteolytic signal that causes the Corpus Luteum to regress. This controlled physiological change typically leads to a subsequent reproductive cycle. The resulting onset of estrus (heat) is usually observed within 2 to 5 days after the injection.

---

Q: How does the structure of Estrumate relate to its function?

The active substance, cloprostenol, is a synthetic analogue of the naturally occurring prostaglandin F2\alpha. The structure is noted to allow the substance to mimic the function of the natural hormone by targeting and activating the FP Prostanoid Receptor. Official documents describe this relationship as key to its luteolytic effect.

---

Q: Is Estrumate the same as other medicines used for fertility issues?

Estrumate is officially classified as a synthetic prostaglandin analogue F2\alpha. This specific classification positions it as a luteolytic agent, meaning it causes the regression of the Corpus Luteum to initiate a new cycle. Its mechanism of action differs from that of other types of medicines used in reproductive management.

---

Q: Can Estrumate affect blood pressure?

While specific changes to blood pressure in the target animals are not explicitly listed in product labeling, the mandatory safety warnings for human handlers provide context. These warnings note a risk of bronchospasm upon accidental exposure, which is related to systemic effects on smooth muscle. The warning is included to highlight the drug’s potential to affect smooth muscle tissue, which requires careful handling.

---

Q: Is there a generic version of Estrumate available?

The active ingredient in Estrumate is cloprostenol. Official sources, such as the FDA, show that cloprostenol is available in multiple approved animal drug products under different brand names, including SYNCHSURE and ESTROPLAN. These products are generally classified as generic or similar animal drug products.

---

Q: Is Estrumate considered a high-risk medication?

Official regulatory documents emphasize the need for caution through mandatory human handler safety warnings. These warnings highlight the risks of accidental exposure, which may cause bronchospasm or, in pregnant women, potential miscarriage or abortion. The presence of these warnings underscores the extreme caution required during handling, as noted in official documents.

---

Q: What are the official sources for checking Estrumate safety and efficacy?

Safety and efficacy information is publicly available from government drug authorities in various countries. Key official sources include the FDA, which publishes information via DailyMed, the European Medicines Agency (EMA), and Health Canada. These bodies provide the full, approved product labels and regulatory details for public review.

---

Q: Does Estrumate carry a Boxed Warning in the US?

While the official label may not explicitly use the term "Boxed Warning," the FDA label contains prominent safety alerts. These include warnings about the risks of severe post-injection bacterial infections (such as clostridial infections) and the serious risks posed to human handlers. These alerts are a high-level caution intended to draw attention to serious safety information.

---

Q: Are the side effects of Estrumate dose-dependent?

Official regulatory documents, specifically the overdose section, describe a dose-response pattern. Mild side effects, such as increased uneasiness, transient diarrhea, and milk letdown, have been detected in studies at levels 50 to 100 times higher than the recommended dose.

How to Store and Dispose of Estrumate?

Estrumate (cloprostenol injection) must be stored and handled according to specific regulatory requirements to maintain product stability.

Storage Conditions

Requirement	Detail
Temperature	Store between 2 C and 30 C (36 F and 86 F). Do not freeze.
Protection	The vial must be kept in the outer carton and protected from light.
Post-Opening Stability	The contents of the multidose vial must be used within 28 days after the first dose is withdrawn.

Disposal Instructions

Unused or expired product must be disposed of via take-back schemes or according to local regulations for pharmaceutical waste. The product must not enter water courses as cloprostenol poses a hazard to aquatic organisms.